2024
Modeling lung adenocarcinoma metastases using patient-derived organoids
Liu Y, Lankadasari M, Rosiene J, Johnson K, Zhou J, Bapat S, Chow-Tsang L, Tian H, Mastrogiacomo B, He D, Connolly J, Lengel H, Caso R, Dunne E, Fick C, Rocco G, Sihag S, Isbell J, Bott M, Li B, Lito P, Brennan C, Bilsky M, Rekhtman N, Adusumilli P, Mayo M, Imielinski M, Jones D. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Reports Medicine 2024, 5: 101777. PMID: 39413736, PMCID: PMC11513837, DOI: 10.1016/j.xcrm.2024.101777.Peer-Reviewed Original ResearchConceptsMetastasis modelLung adenocarcinomaAutologous peripheral blood mononuclear cellsEarly-stage lung cancerMechanisms of drug resistancePeripheral blood mononuclear cellsBlood mononuclear cellsEfficacy of treatmentLung cancer metastasisLung adenocarcinoma metastasisDistant metastasisStudy clonalityAdenocarcinoma metastasisLung cancerMononuclear cellsDrug resistanceMetastasisSuppress metastasisIndividual patientsTumor evolutionCancer metastasisHuman metastasesPatientsBiological featuresRNA sequencingClinicopathologic and Genomic Features Associated with Brain Metastasis After Resection of Lung Adenocarcinoma
Dunne E, Fick C, Mastrogiacomo B, Tan K, Toumbacaris N, Vanstraelen S, Rocco G, Chaft J, Iyengar P, Gomez D, Adusumilli P, Park B, Isbell J, Bott M, Sihag S, Molena D, Huang J, Jones D. Clinicopathologic and Genomic Features Associated with Brain Metastasis After Resection of Lung Adenocarcinoma. JTCVS Open 2024 DOI: 10.1016/j.xjon.2024.09.030.Peer-Reviewed Original ResearchResection of lung adenocarcinomaMaximum standardized uptake valueDevelopment of brain metastasesBrain metastasesStandardized uptake valueNeoadjuvant therapyLung adenocarcinomaAssociated with developmentLymphovascular invasionTP53 mutationsUptake valueCumulative incidence of brain metastasesMarker of aggressive tumor biologyHighest maximum standardized uptake valueLack of extracranial metastasesIncidence of brain metastasesNext-generation sequencingPanel next-generation sequencingAssociated with better survivalStage III diseaseMedian follow-upAggressive tumor biologyBetter performance statusAssociated with brain metastasisStereotactic radiosurgeryLate Recurrence of Completely Resected Stage I-IIIA Lung Adenocarcinoma
Fick C, Dunne E, Toumbacaris N, Tan K, Mastrogiacomo B, Park B, Adusumilli P, Molena D, Gray K, Sihag S, Huang J, Bott M, Rocco G, Isbell J, Jones D. Late Recurrence of Completely Resected Stage I-IIIA Lung Adenocarcinoma. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 38950771, DOI: 10.1016/j.jtcvs.2024.06.026.Peer-Reviewed Original ResearchAggressive pathological featuresLate recurrenceLung adenocarcinomaFollow-upPathological featuresAssociated with late recurrenceElevated risk of recurrenceFactors associated with late recurrenceRetrospective analysis of patientsRecurrence of lung adenocarcinomaHistory of lung cancerStage IIIA diseaseTime of resectionRisk of recurrenceAnalysis of patientsGenomic mutationsNeoadjuvant therapyIIIA diseaseEarly recurrenceClinicopathological variablesLogistic regression modelsRetrospective analysisLung cancerRecurrencePatients
2023
EP07.04-04 High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma
Fick C, Dunne E, Mastrogiacomo B, Tan K, Toumbacaris N, Adusumilli P, Rocco G, Molena D, Huang J, Park B, Bott M, Rusch V, Sihag S, Isbell J, Jones D. EP07.04-04 High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma. Journal Of Thoracic Oncology 2023, 18: s544-s545. DOI: 10.1016/j.jtho.2023.09.1017.Peer-Reviewed Original ResearchStage I lung adenocarcinomaLung adenocarcinomaGenomic mapping of metastatic organotropism in lung adenocarcinoma
Lengel H, Mastrogiacomo B, Connolly J, Tan K, Liu Y, Fick C, Dunne E, He D, Lankadasari M, Satravada B, Sun Y, Kundra R, Fong C, Smith S, Riely G, Rudin C, Gomez D, Solit D, Berger M, Li B, Mayo M, Matei I, Lyden D, Adusumilli P, Schultz N, Sanchez-Vega F, Jones D. Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell 2023, 41: 970-985.e3. PMID: 37084736, PMCID: PMC10391526, DOI: 10.1016/j.ccell.2023.03.018.Peer-Reviewed Original ResearchConceptsActionable alterationsPrimary tumorMetastasis-free survivalHigh mutational burdenAPOBEC mutational signatureSolid histological subtypeMetastatic burdenClinicopathological featuresHistological subtypesLung adenocarcinomaMutational burdenLiver lesionsInactivation of TP53Tumor genomicsMetastasisMetastatic organotropismUnknown significanceGenomic alterationsOrganotropismMutational signaturesTumorsNumber alterationsAlterationsBurdenChromosomal instability